Cargando…

DNA Vaccines against Dengue Virus Type 2 Based on Truncate Envelope Protein or Its Domain III

Two DNA vaccines were constructed encoding the ectodomain (domains I, II and III) of the DENV2 envelope protein (pE1D2) or only its domain III (pE2D2), fused to the human tissue plasminogen activator signal peptide (t-PA). The expression and secretion of recombinant proteins was confirmed in vitro i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Azevedo, Adriana S., Yamamura, Anna M. Y., Freire, Marcos S., Trindade, Gisela F., Bonaldo, Myrna, Galler, Ricardo, Alves, Ada M. B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3136928/ https://www.ncbi.nlm.nih.gov/pubmed/21779317 http://dx.doi.org/10.1371/journal.pone.0020528

Ejemplares similares

The Synergistic Effect of Combined Immunization with a DNA Vaccine and Chimeric Yellow Fever/Dengue Virus Leads to Strong Protection against Dengue
por: Azevedo, Adriana S., et al.
Publicado: (2013)

Construction and characterization of recombinant flaviviruses bearing insertions between E and NS1 genes
por: Bonaldo, Myrna C, et al.
Publicado: (2007)

Diagnostic Performance of Dengue Virus Envelope Domain III in Acute Dengue Infection
por: Nguyen, Ngoc Minh, et al.
Publicado: (2019)

Dengue virus type-3 envelope protein domain III; expression and immunogenicity
por: Fahimi, Hossein, et al.
Publicado: (2014)

Molecular Changes in Dengue Envelope Protein Domain III upon Interaction with Glycosaminoglycans
por: Hyatt, James G., et al.
Publicado: (2020)

Characterization of a dengue type-specific epitope on dengue 3 virus envelope protein domain III
por: Matsui, Kiyohiko, et al.
Publicado: (2010)

Immunogenicity of a novel tetravalent dengue envelope protein domain III-based antigen in mice
por: Fahimi, Hossein, et al.
Publicado: (2018)

Production of dengue 2 envelope domain III in plant using CPMV - based vector system
por: Carlos Marques, Lívia Érika, et al.
Publicado: (2014)

Addition of Partial Envelope Domain II into Envelope Domain III of Dengue Virus Antigen Potentiates the Induction of Virus-Neutralizing Antibodies and Induces Protective Immunity
por: Park, Jisang, et al.
Publicado: (2020)

Neutralizing Antibody Response and Efficacy of Novel Recombinant Tetravalent Dengue DNA Vaccine Comprising Envelope Domain III in Mice
por: Kulkarni, Ajit, et al.
Publicado: (2017)

Immunogenic Subviral Particles Displaying Domain III of Dengue 2 Envelope Protein Vectored by Measles Virus
por: Harahap-Carrillo, Indira S., et al.
Publicado: (2015)

In silico binding analysis of lutein and rosmarinic acid against envelope domain III protein of dengue virus
por: Panchal, Ritesh, et al.
Publicado: (2021)

Casamino acids facilitate the secretion of recombinant dengue virus serotype-3 envelope domain III in Pichia pastoris
por: Kaushik, Neha, et al.
Publicado: (2016)

In silico analysis of an envelope domain III-based multivalent fusion protein as a potential dengue vaccine candidate
por: Fahimi, Hossein, et al.
Publicado: (2016)

Characterization of a Novel Dengue Serotype 4 Virus-Specific Neutralizing Epitope on the Envelope Protein Domain III
por: Ji, Guang-Hui, et al.
Publicado: (2015)

A broadly neutralizing germline-like human monoclonal antibody against dengue virus envelope domain III
por: Hu, Dan, et al.
Publicado: (2019)

Expression of an immunocomplex consisting of Fc fragment fused with a consensus dengue envelope domain III in Saccharomyces cerevisiae
por: So, Kum-Kang, et al.
Publicado: (2021)

Biological and immunological characterization of recombinant Yellow Fever 17D Viruses expressing a Trypanosoma cruzi Amastigote Surface Protein-2 CD8(+ )T cell epitope at two distinct regions of the genome
por: Nogueira, Raquel T, et al.
Publicado: (2011)

Dengue-1 Envelope Protein Domain III along with PELC and CpG Oligodeoxynucleotides Synergistically Enhances Immune Responses
por: Chiang, Chen-Yi, et al.
Publicado: (2012)

Immunogenicity of a novel tetravalent vaccine formulation with four recombinant lipidated dengue envelope protein domain IIIs in mice
por: Chiang, Chen-Yi, et al.
Publicado: (2016)

Dengue Virus Envelope Protein Domain III Induces Nlrp3 Inflammasome-Dependent NETosis-Mediated Inflammation in Mice
por: Lien, Te-Sheng, et al.
Publicado: (2021)

Exposure to Dengue Envelope Protein Domain III Induces Nlrp3 Inflammasome-Dependent Endothelial Dysfunction and Hemorrhage in Mice
por: Lien, Te-Sheng, et al.
Publicado: (2021)

Early IFN-Gamma Production after YF 17D Vaccine Virus Immunization in Mice and Its Association with Adaptive Immune Responses
por: Neves, Patrícia C. C., et al.
Publicado: (2013)

Chimeric Hepatitis B core antigen virus-like particles displaying the envelope domain III of dengue virus type 2
por: Arora, Upasana, et al.
Publicado: (2012)

Simulation of Hemorrhage Pathogenesis in Mice through Dual Stimulation with Dengue Envelope Protein Domain III-Coated Nanoparticles and Antiplatelet Antibody
por: Lien, Te-Sheng, et al.
Publicado: (2023)

Dendritic Cell Targeting Using a DNA Vaccine Induces Specific Antibodies and CD4(+) T Cells to the Dengue Virus Envelope Protein Domain III
por: Zaneti, Arthur Baruel, et al.
Publicado: (2019)

Epitope Presentation of Dengue Viral Envelope Glycoprotein Domain III on Hepatitis B Core Protein Virus-Like Particles Produced in Nicotiana benthamiana
por: Pang, Ee Leen, et al.
Publicado: (2019)

Phage Display Approaches for the Isolation of Monoclonal Antibodies Against Dengue Virus Envelope Domain III from Human and Mouse Derived Libraries
por: Moreland, Nicole J., et al.
Publicado: (2012)

The Immunodominance Change and Protection of CD4(+) T-Cell Responses Elicited by an Envelope Protein Domain III-Based Tetravalent Dengue Vaccine in Mice
por: Chen, Hsin-Wei, et al.
Publicado: (2015)

Evaluation of envelope domain III-based single chimeric tetravalent antigen and monovalent antigen mixtures for the detection of anti-dengue antibodies in human sera
por: Batra, Gaurav, et al.
Publicado: (2011)

A novel platform for virus-like particle-display of flaviviral envelope domain III: induction of Dengue and West Nile virus neutralizing antibodies
por: Chua, Anthony JS, et al.
Publicado: (2013)

Cross-reactivities between human IgMs and the four serotypes of dengue virus as probed with artificial homodimers of domain-III from the envelope proteins
por: Zidane, Nora, et al.
Publicado: (2013)

Lipidated Dengue-2 Envelope Protein Domain III Independently Stimulates Long-Lasting Neutralizing Antibodies and Reduces the Risk of Antibody-Dependent Enhancement
por: Chiang, Chen-Yi, et al.
Publicado: (2013)

Production of tetravalent dengue virus envelope protein domain III based antigens in lettuce chloroplasts and immunologic analysis for future oral vaccine development
por: van Eerde, André, et al.
Publicado: (2019)

Exposure of Platelets to Dengue Virus and Envelope Protein Domain III Induces Nlrp3 Inflammasome-Dependent Platelet Cell Death and Thrombocytopenia in Mice
por: Lien, Te-Sheng, et al.
Publicado: (2021)

HIV envelope tail truncation confers resistance to SERINC5 restriction
por: Haider, Tafhima, et al.
Publicado: (2021)

Dengue virus 4/2 envelope domain chimeric virus panel maps type-specific responses against dengue serotype 2
por: Zhu, Deanna R., et al.
Publicado: (2023)

Pichia pastoris-expressed dengue 3 envelope-based virus-like particles elicit predominantly domain III-focused high titer neutralizing antibodies
por: Tripathi, Lav, et al.
Publicado: (2015)

Zika Virus Envelope Protein Domain III Produced in K. phaffii Has the Potential for Diagnostic Applications
por: Prates, John Willians Oliveira, et al.
Publicado: (2022)

Induction of a Protective Response in Mice by the Dengue Virus NS3 Protein Using DNA Vaccines
por: Costa, Simone M., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_6i3gaqqschcq074gfv6lnvrp58